| The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. | |
| | |
MedLine Citation:
|
PMID: 16268824 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: Ritonavir (RTV) at doses of 400 mg twice a day (bid) or higher adversely affects serum lipids. However, the effect of RTV 100 mg bid on serum lipids is unknown. We conducted a study to evaluate the effect of RTV 100 mg bid on fasting serum lipid profiles in HIV-negative healthy volunteers. METHODS: Ritonavir 100 mg bid was administered for 14 days to 20 healthy HIV-seronegative adults with normal serum lipids. After a 7-day washout, lopinavir/ritonavir (LPV/RTV) 400/100 mg bid was administered for 14 days. Fasting serum lipid parameters were measured twice at baseline, after 14 days of RTV, and after 14 days of LPV/RTV, and comparisons were made at each time-point for levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, the total/HDL cholesterol ratio and triglycerides. RESULTS: After 14 days of RTV 100 mg bid, total cholesterol level increased by 10.2% (P<0.001), LDL cholesterol level increased by 16.2% (P<0.001), triglyceride levels increased by 26.5% (P<0.001), HDL cholesterol level decreased by 5.4% (P<0.01) and the total/HDL cholesterol ratio increased by 17.3% (P<0.001). The addition of LPV 400 mg bid to RTV 100 mg bid resulted in no significant further changes in LDL cholesterol or triglyceride level or total/HDL cholesterol ratio, but there were significant increases in both total cholesterol (8.0% increase; P=0.007) and HDL cholesterol levels (6.7% increase; P=0.008). CONCLUSIONS: Ritonavir dosed at 100 mg bid significantly increased the concentration of total cholesterol, LDL cholesterol, total/HDL cholesterol ratio and triglycerides and reduced HDL cholesterol concentration. The addition of LPV 400 mg bid to RTV 100 mg bid further increased both total and HDL cholesterol levels without affecting the total/HDL ratio. |
| | |
Authors:
|
S D Shafran; L D Mashinter; S E Roberts |
Related Documents
:
|
7092144 - Effect of recent food on estimation of high-density lipoprotein and total cholesterol i... 7351784 - Elevated high-density lipoprotein levels in marathon runners. 7963874 - Cardiovascular risk factors and dietary habits in secondary school children in southern... 1905474 - Serum lipid and apolipoprotein concentrations in healthy men on diets enriched in eithe... 10347814 - Dl-methionine supplementation of rice-and-bean diets affects gamma-glutamyltranspeptida... 12163344 - Cyclo-oxygenase-2 inhibition increases blood pressure in rats. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: HIV medicine Volume: 6 ISSN: 1464-2662 ISO Abbreviation: HIV Med. Publication Date: 2005 Nov |
Date Detail:
|
Created Date: 2005-11-04 Completed Date: 2006-06-29 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 100897392 Medline TA: HIV Med Country: England |
Other Details:
|
Languages: eng Pagination: 421-5 Citation Subset: IM |
Affiliation:
|
Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. sshafran@ualberta.ca |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Cholesterol, HDL / blood Cholesterol, LDL / blood Drug Combinations Fasting / blood* Female HIV Protease Inhibitors / adverse effects* Humans Hyperlipidemias / blood, chemically induced* Male Middle Aged Pyrimidinones / adverse effects Ritonavir / adverse effects* Triglycerides / blood |
| Chemical | |
Reg. No./Substance:
|
0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Drug Combinations; 0/HIV Protease Inhibitors; 0/Pyrimidinones; 0/Ritonavir; 0/Triglycerides; 192725-17-0/lopinavir |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combin...
Next Document: Interaction between ozone and airborne particulate matter in office air.